ARA-290 – 10 mg

Form

Lyophilized powder

Size

10 mg per vial

Type

Synthetic linear 11-amino-acid non-erythropoietic helix-B surface peptide

Formula

C₅₁H₈₄N₁₆O₂₁

Molecular weight

~1,257.3 g/mol

CAS number

1208243-50-8

Amino acids

11

Purity test

HPLC

Identity test

Mass spectrometry

Laboratory

Freedom Diagnostics

ARA-290 is a synthetic peptide derived from the three-dimensional helix-B surface region of erythropoietin (EPO). EPO biology involves two functionally distinct receptor configurations: a homodimeric EPOR/EPOR complex mediating erythropoiesis in erythroid progenitor cells, and a heteromeric EPOR/CD131 (beta-common receptor, βcR) complex — termed the innate repair receptor (IRR) or tissue-protective receptor — that shares the CD131 signaling subunit with the GM-CSF, IL-3, and IL-5 receptors. The foundational EPOR/CD131 heterocomplex characterization was reported by Brines et al. (2004); short tissue-protective helix-B peptide sequences, including the 11-amino-acid precursor of ARA-290, were delimited by Brines et al. (2008). In preclinical cellular systems, IRR engagement is associated with downstream JAK2/STAT3, PI3K/Akt, and ERK pathway activation and with anti-apoptotic transcriptional responses. Mechanistic literature describes IRR expression as locally upregulated in injured, hypoxic, or inflamed tissue rather than constitutively expressed at high levels. ARA-290 has also been reported to interact with TRPV1 channel activity in nociception model systems (Zhang et al., 2016), proposing a direct nociceptor mechanism alongside IRR-mediated anti-inflammatory signaling.